{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T05:16:32Z","timestamp":1768281392448,"version":"3.49.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:p>Mesenchymal stem cells are multipotent cells, with capacity for self-renewal and differentiation into tissues of mesodermal origin. These cells are possible therapeutic agents for autoimmune disorders, since they present remarkable immunomodulatory ability.<\/jats:p>\n              <jats:p>The increase of immune-mediated diseases in veterinary medicine has led to a growing interest in the research of these disorders and their medical treatment. Conventional immunomodulatory drug therapy such as glucocorticoids or other novel therapies such as cyclosporine or monoclonal antibodies are associated with numerous side effects that limit its long-term use, leading to the need for developing new therapeutic strategies that can be more effective and safe.<\/jats:p>\n              <jats:p>The aim of this review is to provide a critical overview about the therapeutic potential of these cells in the treatment of some autoimmune disorders (canine atopic dermatitis, feline chronic gingivostomatitis, inflammatory bowel disease and feline asthma) compared with their conventional treatment.<\/jats:p>\n              <jats:p>Mesenchymal stem cell-based therapy in autoimmune diseases has been showing that this approach can ameliorate clinical signs or even cause remission in most animals, with the exception of canine atopic dermatitis in which little to no improvement was observed.<\/jats:p>\n              <jats:p>Although mesenchymal stem cells present a promising future in the treatment of most of these disorders, the variability in the outcomes of some clinical trials has led to the current controversy among authors regarding their efficacy. Mesenchymal stem cell-based therapy is currently requiring a deeper and detailed analysis that allows its standardization and better adaptation to the intended therapeutic results, in order to overcome current limitations in future trials.<\/jats:p>","DOI":"10.1186\/s12917-019-2087-2","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T04:28:23Z","timestamp":1571804903000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Mesenchymal stem cells therapy in companion animals: useful for immune-mediated diseases?"],"prefix":"10.1186","volume":"15","author":[{"given":"In\u00eas Esteves","family":"Dias","sequence":"first","affiliation":[]},{"given":"Pedro Oliv\u00e9rio","family":"Pinto","sequence":"additional","affiliation":[]},{"given":"Lu\u00eds Carlos","family":"Barros","sequence":"additional","affiliation":[]},{"given":"Carlos Antunes","family":"Viegas","sequence":"additional","affiliation":[]},{"given":"Isabel Ribeiro","family":"Dias","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8916-4276","authenticated-orcid":false,"given":"Pedro Pires","family":"Carvalho","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,10,22]]},"reference":[{"issue":"2","key":"2087_CR1","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1590\/abd1806-4841.20142530","volume":"89","author":"KS Ogliari","year":"2014","unstructured":"Ogliari KS, Marinowic D, Brum DE, Loth F. Stem cells in dermatology. An Bras Dermatol. 2014;89(2):286\u201391.","journal-title":"An Bras Dermatol"},{"key":"2087_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fvets.2018.00070","volume":"5","author":"SH Bogers","year":"2018","unstructured":"Bogers SH. Cell-based therapies for joint disease in veterinary medicine: what we have learned and what we need to know. Front Vet Sci. 2018;5:1\u201317.","journal-title":"Front Vet Sci"},{"key":"2087_CR3","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.ijbiomac.2018.11.158","volume":"123","author":"S Arnhold","year":"2019","unstructured":"Arnhold S, Elashry MI, Klymiuk MC, Wenisch S. Biological macromolecules and mesenchymal stem cells: basic research for regenerative therapies in veterinary medicine. Int J Biol Macromol. 2019;123:889\u201399.","journal-title":"Int J Biol Macromol"},{"key":"2087_CR4","first-page":"8","volume":"9","author":"A Jim\u00e9nez","year":"2017","unstructured":"Jim\u00e9nez A, Guerrero F. C\u00e9lulas madre mesenquimales como nueva terapia en dermatolog\u00eda: conceptos b\u00e1sicos. Rev cl\u00ednica dermatolog\u00eda Vet. 2017;9:8\u201318.","journal-title":"Rev cl\u00ednica dermatolog\u00eda Vet"},{"issue":"1","key":"2087_CR5","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/vde.12000","volume":"24","author":"RJ Harman","year":"2013","unstructured":"Harman RJ. Stem cell therapy in veterinary dermatology. Vet Dermatol. 2013;24(1):90\u2013e24.","journal-title":"Vet Dermatol"},{"issue":"1","key":"2087_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4062\/biomolther.2017.260","volume":"27","author":"AP Ayala-cuellar","year":"2019","unstructured":"Ayala-cuellar AP, Kang J, Jeung E, Choi K. Roles of mesenchymal stem cells in tissue regeneration and immunomodulation. Biomol Ther. 2019;27(1):25\u201333.","journal-title":"Biomol Ther"},{"issue":"2","key":"2087_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1532-950X.2010.00776.x","volume":"40","author":"ND Spencer","year":"2011","unstructured":"Spencer ND, Gimble JM, Lopez MJ. Mesenchymal stromal cells: past, present, and future. Vet Surg. 2011;40(2):129\u201339.","journal-title":"Vet Surg"},{"issue":"1","key":"2087_CR8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/cyto.a.23163","volume":"93","author":"YZ Paterson","year":"2017","unstructured":"Paterson YZ, Kafarnik C, Guest DJ. Characterization of companion animal pluripotent stem cells. Cytom Part A. 2017;93(1):137\u201348.","journal-title":"Cytom Part A."},{"issue":"4","key":"2087_CR9","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/01652176.2013.873963","volume":"33","author":"E De Bakker","year":"2013","unstructured":"De Bakker E, Van Ryssen B, De Schauwer C, Meyer E. Canine mesenchymal stem cells: state of the art, perspectives as therapy for dogs and as a model for man. Vet Q. 2013;33(4):225\u201333.","journal-title":"Vet Q."},{"key":"2087_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/8329174","volume":"1","author":"T Sultana","year":"2018","unstructured":"Sultana T, Lee S, Yoon H, Lee JI. Current status of canine umbilical cord blood-derived mesenchymal stem cells in veterinary medicine. Stem Cells Int. 2018;1:1\u201314.","journal-title":"Stem Cells Int"},{"issue":"1","key":"2087_CR11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.tvjl.2013.03.028","volume":"198","author":"A Cebrian-serrano","year":"2013","unstructured":"Cebrian-serrano A, Stout T, Dinnyes A. Veterinary applications of induced pluripotent stem cells: regenerative medicine and models for disease? Vet J. 2013;198(1):34\u201342.","journal-title":"Vet J"},{"key":"2087_CR12","doi-asserted-by":"publisher","first-page":"389","DOI":"10.5966\/sctm.2014-0110","volume":"4","author":"J Heslop","year":"2015","unstructured":"Heslop J, Hammond T, Santeramo I, et al. Concise Review : workshop Review: understanding and assessing the risks of stem cell-based therapies. Stem Cells Transl Med. 2015;4:389\u2013400.","journal-title":"Stem Cells Transl Med"},{"issue":"3","key":"2087_CR13","doi-asserted-by":"publisher","first-page":"556","DOI":"10.4252\/wjsc.v7.i3.556","volume":"7","author":"MW Klinker","year":"2015","unstructured":"Klinker MW, Wei C-H. Mesenchymal stem cells in the treatment of inflammatory and autoimmune diseases in experimental animal models. World J Stem Cells. 2015;7(3):556\u201367.","journal-title":"World J Stem Cells."},{"issue":"1","key":"2087_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jocit.2014.12.001","volume":"2","author":"Q Zhao","year":"2016","unstructured":"Zhao Q, Ren H, Han Z. Mesenchymal stem cells: immunomodulatory capability and clinical potential in immune diseases. J Cell Immunother. 2016;2(1):3\u201320.","journal-title":"J Cell Immunother"},{"issue":"1","key":"2087_CR15","doi-asserted-by":"publisher","first-page":"e2062","DOI":"10.1038\/cddis.2015.327","volume":"7","author":"F Gao","year":"2016","unstructured":"Gao F, Chiu SM, Motan DAL, Zhang Z, Chen L, Ji H-L, et al. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis. 2016;7(1):e2062.","journal-title":"Cell Death Dis"},{"key":"2087_CR16","first-page":"393","volume":"3","author":"AJ Friedenstein","year":"1970","unstructured":"Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of Guinea-pig bone marrow and spleen cells. Cell Tissue Kinet. 1970;3:393\u2013403.","journal-title":"Cell Tissue Kinet"},{"issue":"3","key":"2087_CR17","doi-asserted-by":"publisher","first-page":"269","DOI":"10.4067\/S0716-97602012000300008","volume":"45","author":"FE Figueroa","year":"2012","unstructured":"Figueroa FE, Carri\u00f3n F, Villanueva S, Khoury M. Mesenchymal stem cell treatment for autoimmune diseases: a critical review. Biol Res. 2012;45(3):269\u201377.","journal-title":"Biol Res"},{"issue":"4","key":"2087_CR18","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1080\/01652176.2013.800250","volume":"33","author":"C Schauwer","year":"2013","unstructured":"Schauwer C, Van de Walle GR, Van Soom A, Meyer E. Mesenchymal stem cell therapy in horses : useful beyond orthopedic injuries ? Vet Q. 2013;33(4):234\u201341.","journal-title":"Vet Q"},{"key":"2087_CR19","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1002\/stem.2377","volume":"34","author":"A Hoffman","year":"2016","unstructured":"Hoffman A, Dow S. Concise Review: stem cell trials using companion animal disease models. Stem Cells Express. 2016;34:1709\u201329.","journal-title":"Stem Cells Express"},{"issue":"3","key":"2087_CR20","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.tvjl.2015.08.003","volume":"206","author":"EM P\u00e9rez-Merino","year":"2015","unstructured":"P\u00e9rez-Merino EM, Us\u00f3n-Casa\u00fas JM, Zaragoza-Bayle C, Duque-Carrasco J, Mari\u00f1as-Pardo L, Hermida-Prieto M, et al. Safety and efficacy of allogeneic adipose tissue-derived mesenchymal stem cells for treatment of dogs with inflammatory bowel disease: clinical and laboratory outcomes. Vet J. 2015;206(3):385\u201390.","journal-title":"Vet J"},{"key":"2087_CR21","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1002\/sctm.17-0035","volume":"6","author":"B Arzi","year":"2017","unstructured":"Arzi B, Clark K, Sundaram A. Therapeutic efficacy of fresh, allogeneic mesenchymal stem cells for severe refractory Gingivostomatitis in Cats. Stem Cells Transl Med. 2017;6:1710\u201322.","journal-title":"Stem Cells Transl Med"},{"issue":"3","key":"2087_CR22","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1177\/1098612X18758590","volume":"20","author":"JM Quimby","year":"2018","unstructured":"Quimby JM, Borjesson DL. Mesenchymal stem cell therapy in cats: current knowledge and future potential. J Feline Med Surg. 2018;20(3):208\u201316.","journal-title":"J Feline Med Surg."},{"issue":"3","key":"2087_CR23","first-page":"207","volume":"63","author":"DD Carrade","year":"2013","unstructured":"Carrade DD, Borjesson DL. Immunomodulation by mesenchymal stem cells in veterinary species. Comp Med. 2013;63(3):207\u201317.","journal-title":"Comp Med"},{"issue":"1","key":"2087_CR24","first-page":"1","volume":"6","author":"SFH De Witte","year":"2016","unstructured":"De Witte SFH, Franquesa M, Baan CC, Hoogduijn MJ. Toward development of iMesenchymal stem cells for immunomodulatory therapy. Front Immunol. 2016;6(1):1\u20139.","journal-title":"Front Immunol"},{"key":"2087_CR25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/rda.12392","volume":"49","author":"N Gon\u00e7alves","year":"2014","unstructured":"Gon\u00e7alves N, Ambr\u00f3sio C, Piedrahita J. Stem cells and regenerative medicine in domestic and companion animals: a multispecies perspective. Reprod Domest Anim. 2014;49:2\u201310.","journal-title":"Reprod Domest Anim"},{"key":"2087_CR26","first-page":"1","volume":"1","author":"MJ Hoogduijn","year":"2015","unstructured":"Hoogduijn MJ. Are mesenchymal stromal cells immune cells? Arthritis Res Ther. 2015;1:1\u20137.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"2087_CR27","doi-asserted-by":"publisher","first-page":"526","DOI":"10.4252\/wjsc.v6.i5.526","volume":"6","author":"JD Glenn","year":"2014","unstructured":"Glenn JD, Whartenby K. Mesenchymal stem cells: emerging mechanisms of immunomodulation and therapy. World J Stem Cells. 2014;6(5):526\u201339.","journal-title":"World J Stem Cells"},{"issue":"4","key":"2087_CR28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini FC, Krause DS, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315\u20137.","journal-title":"Cytotherapy."},{"key":"2087_CR29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1155\/2016\/4157934","volume":"2016","author":"S Malhotra","year":"2016","unstructured":"Malhotra S, Hu MS, Marshall CD, Leavitt T, Cheung ATM, Gonzalez JG, et al. Mesenchymal stromal cells as cell-based therapeutics for wound healing. Stem Cells Int. 2016;2016:2\u20137.","journal-title":"Stem Cells Int"},{"key":"2087_CR30","doi-asserted-by":"publisher","first-page":"1):1","DOI":"10.3389\/fendo.2016.00171","volume":"7","author":"ME Bateman","year":"2017","unstructured":"Bateman ME, Strong AL, McLachlan JA, Burow ME, Bunnell BA. The effects of endocrine disruptors on adipogenesis and osteogenesis in mesenchymal stem cells: a review. Front Endocrinol. 2017;7:1):1\u201312.","journal-title":"Front Endocrinol"},{"issue":"2","key":"2087_CR31","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s12015-014-9583-3","volume":"11","author":"M Gazdic","year":"2015","unstructured":"Gazdic M, Volarevic V, Arsenijevic N, Stojkovic M. Mesenchymal stem cells: a friend or foe in immune-mediated diseases. Stem Cell Rev Reports. 2015;11(2):280\u20137.","journal-title":"Stem Cell Rev Reports"},{"issue":"3","key":"2087_CR32","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.stem.2008.07.003","volume":"3","author":"M Crisan","year":"2008","unstructured":"Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell. 2008;3(3):301\u201313.","journal-title":"Cell Stem Cell"},{"key":"2087_CR33","first-page":"1","volume":"0","author":"CL Esteves","year":"2018","unstructured":"Esteves CL, Donadeu FX. Pericytes and their potential in regenerative medicine across species. Cytom Part A. 2018;0:1\u201310.","journal-title":"Cytom Part A"},{"issue":"16","key":"2087_CR34","doi-asserted-by":"publisher","first-page":"6503","DOI":"10.1073\/pnas.1015449108","volume":"108","author":"J Feng","year":"2011","unstructured":"Feng J, Mantesso A, De BC, Nishiyama A, Sharpe PT. Dual origin of mesenchymal stem cells contributing to organ growth and repair. PNAS. 2011;108(16):6503\u20138.","journal-title":"PNAS."},{"issue":"2","key":"2087_CR35","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.cveq.2011.06.003","volume":"27","author":"JF Peroni","year":"2011","unstructured":"Peroni JF, Borjesson DL. Anti-inflammatory and immunomodulatory activities of stem cells. Vet Clin North Am - Equine Pract. 2011;27(2):351\u201362.","journal-title":"Vet Clin North Am - Equine Pract"},{"issue":"13","key":"2087_CR36","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1007\/s00018-017-2473-5","volume":"74","author":"N Li","year":"2017","unstructured":"Li N, Hua J. Interactions between mesenchymal stem cells and the immune system. Cell Mol Life Sci. 2017;74(13):2345\u201360.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"2087_CR37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1042\/CS20171154","volume":"132","author":"S-H Yang","year":"2018","unstructured":"Yang S-H, Gao C-Y, Li L, Chang C, Leung PSC, Gershwin ME, et al. The molecular basis of immune regulation in autoimmunity. Clin Sci. 2018;132(1):43\u201367.","journal-title":"Clin Sci"},{"issue":"1","key":"2087_CR38","doi-asserted-by":"publisher","first-page":"54","DOI":"10.15283\/ijsc.2015.8.1.54","volume":"8","author":"N Kim","year":"2015","unstructured":"Kim N, Cho S-G. New strategies for overcoming limitations of mesenchymal stem cell-based immune modulation. Int J stem cells. 2015;8(1):54\u201368.","journal-title":"Int J stem cells"},{"issue":"12","key":"2087_CR39","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1002\/sctm.17-0129","volume":"6","author":"RM Samsonraj","year":"2017","unstructured":"Samsonraj RM, Raghunath M, Nurcombe V, Hui JH, van Wijnen AJ, Cool SM. Concise Review: multifaceted characterization of human mesenchymal stem cells for use in regenerative medicine. Stem Cells Transl Med. 2017;6(12):2173\u201385.","journal-title":"Stem Cells Transl Med"},{"key":"2087_CR40","volume-title":"Veterinary Immunology An Introduction","author":"IR Tizard","year":"2004","unstructured":"Tizard IR. In: Saunders, editor. Veterinary Immunology An Introduction. 7th ed. Texas: Saunders; 2004.","edition":"7"},{"issue":"12","key":"2087_CR41","first-page":"1445","volume":"37","author":"J Kim","year":"2009","unstructured":"Kim J, Hematti P. Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Natl Institutes Heal. 2009;37(12):1445\u201353.","journal-title":"Natl Institutes Heal."},{"issue":"2","key":"2087_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0009252","volume":"5","author":"J Maggini","year":"2010","unstructured":"Maggini J, Mirkin G, Bognanni I, Holmberg J, Piazzo IM, Can C, et al. Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PLoS One. 2010;5(2):1\u201313.","journal-title":"PLoS One"},{"issue":"3","key":"2087_CR43","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.4049\/jimmunol.180.3.1598","volume":"180","author":"Y-P Li","year":"2008","unstructured":"Li Y-P, Paczesny S, Lauret E, Poirault S, Bordigoni P, Mekhloufi F, et al. Human mesenchymal stem cells license adult CD34+ Hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the notch pathway. J Immunol. 2008;180(3):1598\u2013608.","journal-title":"J Immunol"},{"issue":"3","key":"2087_CR44","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1182\/blood-2007-02-074997","volume":"111","author":"GM Spaggiari","year":"2008","unstructured":"Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Cristina M, Moretta L, et al. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood J. 2008;111(3):1327\u201333.","journal-title":"Blood J"},{"issue":"1","key":"2087_CR45","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1182\/blood-2005-07-2657","volume":"107","author":"A Corcione","year":"2006","unstructured":"Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Risso M, et al. Human mesenchymal stem cells modulate B-cell functions. Blood J. 2006;107(1):367\u201372.","journal-title":"Blood J"},{"key":"2087_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2012.00212","volume":"3","author":"M Franquesa","year":"2012","unstructured":"Franquesa M, Hoogduijn MJ, Bestard O, Griny\u00f3 JM. Immunomodulatory effect of mesenchymal stem cells on B cells. Front Immunol. 2012;3:1\u20137.","journal-title":"Front Immunol"},{"issue":"3","key":"2087_CR47","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00251-011-0577-x","volume":"64","author":"JB Roque","year":"2012","unstructured":"Roque JB, O\u2019Leary CA, Duffy DL, Kyaw-Tanner M, Gharahkhani P, Vogelnest L, et al. Atopic dermatitis in West Highland white terriers is associated with a 1.3-Mb region on CFA 17. Immunogenetics. 2012;64(3):209\u201317.","journal-title":"Immunogenetics."},{"issue":"2","key":"2087_CR48","first-page":"1","volume":"26","author":"P Bizikova","year":"2015","unstructured":"Bizikova P, Pucheu-Haston CM, Eisenschenk MNC, Marsella R, Nuttall T, Review SD. Role of genetics and the environment in the pathogenesis of canine atopic dermatitis. Vet Dermatol. 2015;26(2):1\u201310.","journal-title":"Vet Dermatol"},{"issue":"2","key":"2087_CR49","first-page":"1","volume":"26","author":"P Bizikova","year":"2015","unstructured":"Bizikova P, Santoro D, Marsella R, Nuttall T, Eisenschenk MNC, Pucheu-Haston CM. Review: clinical and histological manifestations of canine atopic dermatitis. Vet Dermatol. 2015;26(2):1\u20136.","journal-title":"Vet Dermatol"},{"issue":"2","key":"2087_CR50","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/vde.12205","volume":"26","author":"CM Pucheu-Haston","year":"2015","unstructured":"Pucheu-Haston CM, Bizikova P, Marsella R, Santoro D, Nuttall T, Eisenschenk MNC. Review: lymphocytes, cytokines, chemokines and the T-helper 1-T-helper 2 balance in canine atopic dermatitis. Vet Dermatol. 2015;26(2):124\u2013e32.","journal-title":"Vet Dermatol"},{"issue":"1","key":"2087_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12917-014-0312-6","volume":"11","author":"T Olivry","year":"2015","unstructured":"Olivry T, DeBoer DJ, Favrot C, Jackson HA, Mueller RS, Nuttall T, et al. Treatment of canine atopic dermatitis: 2015 updated guidelines from the international committee on allergic diseases of animals (ICADA). BMC Vet Res. 2015;11(1):1\u201315.","journal-title":"BMC Vet Res"},{"issue":"6","key":"2087_CR52","first-page":"1","volume":"27","author":"GM Michels","year":"2016","unstructured":"Michels GM, Ramsey DS, Walsh KF, Martinon OM, Mahabir SP, Hoevers JD, et al. A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab ( ZTS-00103289 ), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis. Vet Dermatol. 2016;27(6):1\u201312.","journal-title":"Vet Dermatol"},{"key":"2087_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/vde.12478","volume":"28","author":"H Moyaert","year":"2017","unstructured":"Moyaert H, Van BL, Borowski S, Escalada M, Mahabir SP, Walters RR, et al. A blinded , randomized clinical trial evaluating the efficacy and safety of lokivetmab compared to ciclosporin in client-owned dogs with atopic dermatitis. Vet Dermatol. 2017;28:1\u201313.","journal-title":"Vet Dermatol"},{"issue":"2","key":"2087_CR54","first-page":"E1","volume":"11","author":"MN Hall","year":"2010","unstructured":"Hall MN, Rosenkrantz WS, Hong JH, Griffin CE, Mendelsohn CM. Evaluation of the potential use of adipose-derived mesenchymal stromal cells in the treatment of canine atopic dermatitis: a pilot study. Vet Ther. 2010;11(2):E1\u201314.","journal-title":"Vet Ther"},{"key":"2087_CR55","doi-asserted-by":"publisher","first-page":"75","DOI":"10.5966\/sctm.2015-0127","volume":"5","author":"B Arzi","year":"2016","unstructured":"Arzi B, Bateman ME, Strong AL, McLachlan JA, Burrow MEBB, Vapniarsky N, Mills-Ko E, Verstraete FJM, Fazel N, et al. Therapeutic efficacy of fresh, autologous mesenchymal stem cells for severe refractory Gingivostomatitis in cats. Stem Cells Transl Med. 2016;5:75\u201386.","journal-title":"Stem Cells Transl Med"},{"key":"2087_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fvets.2016.00054","volume":"3","author":"JN Winer","year":"2016","unstructured":"Winer JN, Arzi B, Verstraete FJM. Therapeutic Management of Feline Chronic Gingivostomatitis: a systematic Review of the literature. Front Vet Sci. 2016;3:1\u201310.","journal-title":"Front Vet Sci."},{"issue":"1","key":"2087_CR57","first-page":"27","volume":"7","author":"B Greenfield","year":"2017","unstructured":"Greenfield B. Chronic feline Gingivostomatitis: Proven Therapeutic Approaches & new Treatment Options. Today\u2019s Vet Pract. 2017;7(1):27\u201338.","journal-title":"Today\u2019s Vet Pract."},{"issue":"6","key":"2087_CR58","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1111\/jvim.14850","volume":"31","author":"MI Kouki","year":"2017","unstructured":"Kouki MI, Papadimitriou SA, Psalla D, Kolokotronis A, Rallis TS. Chronic Gingivostomatitis with esophagitis in cats. J Vet Intern Med. 2017;31(6):1673\u20139.","journal-title":"J Vet Intern Med"},{"issue":"3","key":"2087_CR59","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.cvsm.2013.02.004","volume":"43","author":"MJ Lommer","year":"2013","unstructured":"Lommer MJ. Oral inflammation in small animals. Vet Clin North Am - Small Anim Pract. 2013;43(3):555\u201371.","journal-title":"Vet Clin North Am - Small Anim Pract"},{"key":"2087_CR60","first-page":"15):1","volume":"6","author":"N Johnston","year":"2015","unstructured":"Johnston N. Feline chronic gingivitis stomatitis. Dentalvets. 2015;6:15):1\u201314.","journal-title":"Dentalvets."},{"issue":"1","key":"2087_CR61","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1177\/089875641303000101","volume":"30","author":"MJ Lommer","year":"2013","unstructured":"Lommer MJ. Efficacy of cyclosporine for chronic, refractory stomatitis in cats: a randomized, placebo-controlled, double-blinded clinical study. J Vet Dent. 2013;30(1):8\u201317.","journal-title":"J Vet Dent"},{"issue":"4","key":"2087_CR62","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1177\/089875640702400406","volume":"24","author":"JR Lewis","year":"2007","unstructured":"Lewis JR, Tsugawa AJ, Reiter AM. Use of CO2 laser as an adjunctive treatment for caudal stomatitis in a cat. J Vet Dent. 2007;24(4):240\u20139.","journal-title":"J Vet Dent"},{"key":"2087_CR63","volume-title":"Textbook of veterinary internal medicine","author":"SJ Ettinger","year":"2017","unstructured":"Ettinger SJ. Textbook of veterinary internal medicine. 8th ed. Missouri: Elsevier; 2017.","edition":"8"},{"issue":"1","key":"2087_CR64","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2478\/v10181-011-0026-7","volume":"14","author":"K Malewska","year":"2011","unstructured":"Malewska K, Rychlik A, Nieradka R, Kander M. Treatment of inflammatory bowel disease (IBD) in dogs and cats. Pol J Vet Sci. 2011;14(1):165\u201371.","journal-title":"Pol J Vet Sci"},{"key":"2087_CR65","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/jsap.12588","volume":"57","author":"JRS Dandrieux","year":"2016","unstructured":"Dandrieux JRS. Inflammatory bowel disease versus chronic enteropathy in dogs: are they one and the same ? J Small Anim Pract. 2016;57:589\u201399.","journal-title":"J Small Anim Pract"},{"issue":"1","key":"2087_CR66","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2217\/rme.15.69","volume":"11","author":"L Ferrer","year":"2016","unstructured":"Ferrer L, Kimbrel EA, Lam A, Falk EB, Zewe C, Juopperi T, et al. Treatment of perianal fistulas with human embryonic stem cell-derived mesenchymal stem cells: a canine model of human fistulizing Crohn\u2019s disease. Regen Med. 2016;11(1):33\u201343.","journal-title":"Regen Med"},{"key":"2087_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tvjl.2015.07.007","volume":"206","author":"EM P\u00e9rez-Merino","year":"2015","unstructured":"P\u00e9rez-Merino EM, Us\u00f3n-Casa\u00fas JM, Duque-Carrasco J, Zaragoza-Bayle C, Mari\u00f1as-Pardo L, Hermida-Prieto M, Vilafranca-Compte M, Barrera-Chac\u00f3n R, Gualtieri M. Safety and efficacy of allogeneic adipose tissue-derived mesenchymal stem cells for treatment of dogs with inflammatory bowel disease: endoscopic and histological outcomes. Vet J. 2015;206:1\u201323.","journal-title":"Vet J"},{"issue":"2","key":"2087_CR68","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.cvsm.2011.02.003","volume":"41","author":"KW Simpson","year":"2011","unstructured":"Simpson KW, Jergens AE. Pitfalls and Progress in the diagnosis and Management of Canine Inflammatory Bowel Disease. Vet Clin North Am - Small Anim Pract. 2011;41(2):381\u201398.","journal-title":"Vet Clin North Am - Small Anim Pract."},{"issue":"10","key":"2087_CR69","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1177\/1098612X14561105","volume":"17","author":"TL Webb","year":"2015","unstructured":"Webb TL, Webb CB. Stem cell therapy in cats with chronic enteropathy: a proof-of-concept study. J Feline Med Surg. 2015;17(10):901\u20138.","journal-title":"J Feline Med Surg."},{"issue":"1","key":"2087_CR70","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.cvsm.2013.08.006","volume":"44","author":"JE Trzil","year":"2014","unstructured":"Trzil JE, Reinero CR. Update on feline asthma. Vet Clin North Am - Small Anim Pract. 2014;44(1):91\u2013105.","journal-title":"Vet Clin North Am - Small Anim Pract."},{"issue":"12","key":"2087_CR71","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1177\/1098612X15604351","volume":"18","author":"JE Trzil","year":"2016","unstructured":"Trzil JE, Masseau I, Webb TL, Chang C-H, Dodam JR, Liu H, et al. Intravenous adipose-derived mesenchymal stem cell therapy for the treatment of feline asthma: a pilot study. J Feline Med Surg. 2016;18(12):981\u201390.","journal-title":"J Feline Med Surg"},{"issue":"1","key":"2087_CR72","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.tvjl.2010.09.022","volume":"190","author":"CR Reinero","year":"2011","unstructured":"Reinero CR. Advances in the understanding of pathogenesis, and diagnostics and therapeutics for feline allergic asthma. Vet J. 2011;190(1):28\u201333.","journal-title":"Vet J"},{"issue":"2","key":"2087_CR73","first-page":"28","volume":"4","author":"C Sharp","year":"2014","unstructured":"Sharp C. Treatment of feline lower airway disease. Today\u2019s Vet Pract. 2014;4(2):28\u201332.","journal-title":"Today\u2019s Vet Pract"},{"key":"2087_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/JLB.3MR1117-436R","volume":"104","author":"HF Rosenberg","year":"2018","unstructured":"Rosenberg HF, Druey KM. Modeling asthma: pitfalls, promises, and the road ahead. J Leukoc Biol. 2018;104:1\u20138.","journal-title":"J Leukoc Biol"},{"key":"2087_CR75","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.vetimm.2008.12.008","volume":"129","author":"TM Lee-Fowler","year":"2009","unstructured":"Lee-Fowler TM, Cohn LA, DeClue AE, Spinka CM, Reinero CR. Evaluation of subcutaneous versus mucosal (intranasal) allergen-specific rush immunotherapy in experimental feline asthma. Vet Immunol Immunopathol. 2009;129:49\u201356.","journal-title":"Vet Immunol Immunopathol"},{"issue":"4","key":"2087_CR76","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1159\/000335122","volume":"158","author":"TM Lee-Fowler","year":"2012","unstructured":"Lee-Fowler TM, Guntur V, Dodam J, Cohn LA, Declue AE, Reinero CR. The tyrosine kinase inhibitor masitinib blunts airway inflammation and improves associated lung mechanics in a feline model of chronic allergic asthma. Int Arch Allergy Immunol. 2012;158(4):369\u201374.","journal-title":"Int Arch Allergy Immunol"},{"key":"2087_CR77","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1038\/sj.bjp.0701716","volume":"123","author":"RW Mitchell","year":"1998","unstructured":"Mitchell RW, Cozzi P, Ndukwu IM, Spaethe S, Le AR, Padrid PA. Differential effects of cyclosporine a after acute antigen challenge in sensitized cats in vivo and ex vivo. Br J Pharmacol. 1998;123:1198\u2013204.","journal-title":"Br J Pharmacol"},{"issue":"6","key":"2087_CR78","first-page":"426","volume":"27","author":"C Byers","year":"2005","unstructured":"Byers C, Dhupa N. Feline bronchial asthma: treatment. Compend Contin Educ Pract Vet. 2005;27(6):426\u201332.","journal-title":"Compend Contin Educ Pract Vet"},{"issue":"12","key":"2087_CR79","first-page":"1546","volume":"44","author":"JE Trzil","year":"2014","unstructured":"Trzil JE, Masseau I, Webb TL, Chang C, Dodam JR, Cohn LA, et al. Long term evaluation of mesenchymal stem cell therapy in a feline model of chronic allergic asthma. Natl Institutes Heal. 2014;44(12):1546\u201357.","journal-title":"Natl Institutes Heal"},{"issue":"1","key":"2087_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-017-0742-8","volume":"8","author":"AK Berglund","year":"2017","unstructured":"Berglund AK, Fortier LA, Antczak DF, Schnabel LV. Immunoprivileged no more: measuring the immunogenicity of allogeneic adult mesenchymal stem cells. Stem Cell Res Ther. 2017;8(1):1\u20137.","journal-title":"Stem Cell Res Ther"},{"key":"2087_CR81","first-page":"168","volume":"13","author":"D Jayne","year":"2004","unstructured":"Jayne D, Tynsall A. Autologous hematopoietic stem cell transplantation for systemic lupus erythematosus. Biol Blood Marrow Transplant. 2004;13:168\u201376.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2087_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3727\/096368915X688173","volume":"25","author":"E Jang","year":"2016","unstructured":"Jang E, Jeong M, Kim S, Jang K, Kang B-K, Lee DY, et al. Infusion of human bone marrow-derived mesenchymal stem cells alleviates autoimmune nephritis in a lupus model by suppressing follicular helper T-cell development. Cell Transplant. 2016;25(1):1\u201315.","journal-title":"Cell Transplant"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-019-2087-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12917-019-2087-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-019-2087-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T23:16:59Z","timestamp":1603235819000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcvetres.biomedcentral.com\/articles\/10.1186\/s12917-019-2087-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,22]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2087"],"URL":"https:\/\/doi.org\/10.1186\/s12917-019-2087-2","relation":{},"ISSN":["1746-6148"],"issn-type":[{"value":"1746-6148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,22]]},"assertion":[{"value":"24 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"P.P.C. declares to be the founder and CEO of Vetherapy, a biotech company focused on regenerative products. P.P.C. also declares that his company had no influence or involvement with any of the results in analysis in this study. The remaining authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"358"}}